<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03585777</url>
  </required_header>
  <id_info>
    <org_study_id>VCG 3</org_study_id>
    <nct_id>NCT03585777</nct_id>
  </id_info>
  <brief_title>Compare Serum Klotho Levels in Patients on Oral Antidiabetic Treatment</brief_title>
  <official_title>Serum Klotho Level in Patients on Oral Antidiabetic Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fayoum University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fayoum University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Klotho is a protein found in serum, kidney,heart,brain and in other tissues,it has many&#xD;
      functions,it is viewed as the anti aging hormone. Aging kidneys are characterized by&#xD;
      progressive scarring and measurable declines in renal function&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives To study serum klotho level among diabetic patients attending diabetes and&#xD;
      endocrine clinic in Fayoum university on oral antidiabetic treatment&#xD;
&#xD;
      Study Design:&#xD;
&#xD;
      This study will be an observational prospective cohort study. The study duration will be 2&#xD;
      months.&#xD;
&#xD;
      Study Methods:&#xD;
&#xD;
        -  Population of Study&#xD;
&#xD;
        -  Group 1 :compare serum klotho levels in patients taking glimeperirde versus levels in&#xD;
           patients taking metformin&#xD;
&#xD;
        -  Group 2 : compare serum klotho levels in patients taking glimeperirde versus levels in&#xD;
           patients taking linagliptin&#xD;
&#xD;
        -  Group 3 : compare serum klotho levels in patients taking glimeperirde versus levels in&#xD;
           patients taking impaglifluzin&#xD;
&#xD;
        -  Inclusion Criteria :&#xD;
&#xD;
        -  Group 1 :Diabetics candidate for oral treatment&#xD;
&#xD;
        -  Group 2 :Diabetics candidate for oral treatment&#xD;
&#xD;
        -  Group 3 :Diabetics candidate for oral treatment&#xD;
&#xD;
        -  Exclusion Criteria :&#xD;
&#xD;
      Diabetics candidate for insulin treatment&#xD;
&#xD;
      There will be three arms to this study; the first arm will enroll patients on glimepiride and&#xD;
      patients on metformin to compare serum klotho levels. The second arm will enroll patients on&#xD;
      glimepiride and patients on linagliptin to compare serum klotho levels. The third arm will&#xD;
      enroll patients on glimepiride and patients on impaglifluzin to compare serum klotho levels&#xD;
      Each arm will enroll 40 patients, 20 patients on glimiperide treatment,20 patient will on the&#xD;
      other drug,patients will be selected from Fayoum university diabetes and endocrine clinic&#xD;
&#xD;
      Data collection:&#xD;
&#xD;
      Patients will be subjected to; full clinical examination,waist hip ratio assessment,BMI&#xD;
      assessment fasting blood glucose,2PP blood glucose,HbA1C, urea, creatinine, uric acid total&#xD;
      calcium,albumin, phospherus, estimated GFR, ACR, total cholesterol, triglycerides, serum&#xD;
      klotho, FGF 23 levels assessment , also fracrtional excretion of phospherus will be assessed.&#xD;
      Control of blood glucose will be done along the period of the study. At the end of the 2&#xD;
      months,reassessment of the above mentioned parameters will be done.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">October 11, 2018</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Months</target_duration>
  <primary_outcome>
    <measure>Beneficial effect manifested by a statistical significant decrease in klotho levels</measure>
    <time_frame>2 months</time_frame>
    <description>An anticipated statistical significant decrease in klotho level</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>No beneficial effect manifested by by a non significant decrease in klotho level or a rise in the level</measure>
    <time_frame>2 months</time_frame>
    <description>Non statistical significant decrease in klotho level, or a significant rise in it</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Compare Serum Level of Klotho in Patients on Oral Antidiabetic Treatment</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <description>Compare serum levels of klotho in patients taking glimepiride in comparison to patients taking metformin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <description>Compare serum levels of klotho in patients taking glimepiride in comparison to patients taking linagliptin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <description>Compare serum levels of klotho in patients taking glimepiride in comparison to patients taking impaglifluzin</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        type 2 diabetics on oral treatment&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diabetics candidate for oral treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diabetics candidate for insulin treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ahmed Hammad, MD</last_name>
    <phone>00201001574639</phone>
    <email>aah12@fayoum.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mohammed Mashaheet, MD</last_name>
    <phone>00201227904660</phone>
    <email>mam22@fayoum.edu.eg</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fayoum university Hospital</name>
      <address>
        <city>Fayoum</city>
        <country>Egypt</country>
      </address>
    </facility>
    <contact>
      <last_name>Ahmed Hammad, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>February 9, 2018</study_first_submitted>
  <study_first_submitted_qc>June 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 13, 2018</study_first_posted>
  <last_update_submitted>June 30, 2018</last_update_submitted>
  <last_update_submitted_qc>June 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fayoum University</investigator_affiliation>
    <investigator_full_name>Ahmed Abdelkawi Hammad</investigator_full_name>
    <investigator_title>Lecturer of internal medicine,faculty of medicine,Fayoum university</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

